Insulet Corporation, a medical device company, develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The Company offers Omnipod Insulin Management System (Omnipod System), which consists of the OmniPod, an easy-to-use continuous insulin delivery system and Personal Diabetes Manager, a handheld wireless device. It also customizes the Omnipod System technology platform for the delivery of subcutaneous drugs across various therapeutic areas. Insulet Corporation sells and markets its Omnipod System through a combination of direct sales representatives and independent distributors.

Type
Public
HQ
Billerica, US
Founded
2000
Size (employees)
640 (est)
Insulet Corporation was founded in 2000 and is headquartered in Billerica, US
Report incorrect company information

Key People/Management at Insulet Corporation

Patrick Sullivan

Patrick Sullivan

Chairman of the Board and Chief Executive Officer
Aiman Abdel-Malek

Aiman Abdel-Malek

Senior Vice President, Advanced Technology and Engineering
Bret Christensen

Bret Christensen

Senior Vice President and Chief Commercial Officer
David Colleran

David Colleran

Senior Vice President, Secretary and General Counsel
Deborah Gordon

Deborah Gordon

Vice President, Investor Relations and Corporate Communications
Michael Levitz

Michael Levitz

Senior Vice President, Chief Financial Officer and Treasurer
Show more

Insulet Corporation Office Locations

Insulet Corporation has offices in Billerica, Denver, Tulsa, Washington and in 11 other locations
Billerica, US (HQ)
200 600 Technology Park Dr
Show all (15)
Report incorrect company information

Insulet Corporation Financials and Metrics

Insulet Corporation Financials

Insulet Corporation's revenue was reported to be $366.99 m in FY, 2016 which is a 13.2% increase from the previous period.
USD

Revenue (Q1, 2018)

123.6 m

Gross profit (Q1, 2018)

75.8 m

Gross profit margin (Q1, 2018), %

61.3%

Net income (Q1, 2018)

(6.6 m)

Market capitalization (14-Jun-2018)

5.8 b

Closing share price (14-Jun-2018)

99.1

Cash (31-Mar-2018)

203.1 m
Insulet Corporation's current market capitalization is $5.8 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

247.1 m288.7 m324.2 m367 m

Revenue growth, %

17%12%13%

Cost of goods sold

134.7 m145.4 m176.1 m155.9 m

Gross profit

112.4 m143.3 m148.2 m211.1 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

61.1 m69.2 m72 m75 m61.2 m75.6 m87.3 m81.2 m87.3 m94.9 m101.7 m109.8 m123.6 m

Cost of goods sold

33.7 m36.4 m36.2 m36.9 m28.4 m41.2 m51.7 m37.2 m36.9 m39.2 m42.3 m45.1 m47.8 m

Gross profit

27.4 m32.8 m35.8 m38 m32.8 m34.4 m35.7 m44.1 m50.5 m55.6 m59.4 m64.6 m75.8 m

Gross profit Margin, %

45%47%50%51%54%45%41%54%58%59%58%59%61%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

149.7 m151.2 m122.7 m137.2 m

Accounts Receivable

33.1 m39.9 m48.4 m28.8 m

Inventories

9.5 m13.1 m5.7 m35.5 m

Current Assets

198.2 m208.2 m190.8 m370 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

153.9 m145.6 m175.5 m146.4 m145.6 m145.1 m145.5 m111.6 m75.7 m215.4 m76 m73.5 m203.1 m

Accounts Receivable

34.5 m36.7 m41.8 m47.1 m36.1 m31.8 m31.8 m40.5 m38.7 m38.5 m40.6 m37.8 m50.4 m

Inventories

5.4 m10.4 m8.8 m9.7 m20.1 m23.4 m13 m14 m24.5 m32.7 m34.3 m34 m26.3 m

Current Assets

199.7 m199.9 m231.8 m206.6 m205.4 m203.8 m194.3 m171.8 m181.3 m361.8 m337.2 m338.7 m451.6 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(45 m)(51.5 m)(73.5 m)(28.9 m)

Depreciation and Amortization

11.8 m12.2 m15.8 m13.8 m

Inventories

5.4 m(3.6 m)(722 k)(24.1 m)

Cash From Operating Activities

3.3 m8.9 m(12.6 m)15.9 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

(42.5 m)(6.1 m)(35.3 m)(46.1 m)(11.8 m)(27.3 m)(46.2 m)(12.5 m)(16.7 m)(19.8 m)(10 m)(17.7 m)(6.6 m)

Depreciation and Amortization

8.9 m3.1 m6.1 m9.2 m3.4 m7.1 m11.4 m3.4 m6.8 m10.5 m3.3 m6.7 m3.5 m

Inventories

9.5 m(985 k)699 k(198 k)(7 m)(10.3 m)312 k(2.6 m)(13.1 m)(21.3 m)1.2 m1.5 m6.7 m

Cash From Operating Activities

6.9 m(1 m)(509 k)4.3 m(3.5 m)(2.7 m)(10.5 m)(6.8 m)(4.2 m)(21.8 m)(3.9 m)(4.3 m)
USDY, 2018

Financial Leverage

4.9 x
Show all financial metrics

Insulet Corporation Operating Metrics

FY, 2016

Patents Issued

23

Patents Pending

32
Show all operating metrics

Insulet Corporation Revenue Breakdown

Embed Graph

Insulet Corporation revenue breakdown by business segment: 62.6% from U.S. Omnipod, 19.6% from International Omnipod and 17.8% from Drug Delivery

Report incorrect company information

Insulet Corporation Online and Social Media Presence

Embed Graph
Report incorrect company information